0000885590-13-000016.txt : 20130306
0000885590-13-000016.hdr.sgml : 20130306
20130306191412
ACCESSION NUMBER: 0000885590-13-000016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130128
FILED AS OF DATE: 20130306
DATE AS OF CHANGE: 20130306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Weldon Ryan
CENTRAL INDEX KEY: 0001564233
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 13671145
MAIL ADDRESS:
STREET 1: 4787 LEVY STREET
CITY: MONTREAL
STATE: A8
ZIP: H4R 2P9
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4787 LEVY STREET
STREET 2: MONTREAL
CITY: QUEBEC
STATE: A8
ZIP: H4R 2P9
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 4787 LEVY STREET
STREET 2: MONTREAL
CITY: QUEBEC
STATE: A8
ZIP: H4R 2P9
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2013-01-28
0
0000885590
Valeant Pharmaceuticals International, Inc.
VRX
0001564233
Weldon Ryan
4787 LEVY STREET
MONTREAL
A8
H4R 2P9
QUEBEC, CANADA
0
1
0
0
EVP, Company Group Chairman
Non-Qualified Stock (rights to purchase)
69.41
2013-03-05
4
A
0
13700
0
A
2017-03-05
2023-03-05
Common Shares, no par value
13700
13700
D
Restricted Share Units
0
2013-01-28
4
A
0
11000
0
A
Common Shares, no par value
11000
11000
D
The options vest 25% per year for 4 years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant and the fourth vest date falling on the fourth anniversary of the grant.
Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (3).
The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $62.62 on each of three measurement dates: 25% would vest on October 28, 2015, 50% on January 28, 2016 and 25% on April 28, 2016, with early vesting possible at higher TSR levels.
by: Nicholas Zanoni for Ryan Weldon
2013-03-06